My Companies
Notification
Account
Log Out
Login
API subsidiarization completed; InvAscent investment for 40% RPGAP; Actis Generics and Raghava acquisitions announced, adding 300KL capacity and ~₹200Cr revenue potential.
RPG Life Sciences Agrees To Acquire Raghava API Business For ₹135 Crore
RPG Life Sciences Approves Up To ₹135 Crore Raghava API Acquisition
RPG Life Sciences Approves ₹135 Crore API Business Acquisition
RPG Life Sciences Carves Out API Business, Raises ₹243 Crore From InvAscent
RPG Life Sciences Approves ₹243 Crore API Subsidiary Investment And Acquisition